Free Standard AU & NZ Shipping For All Book Orders Over $80!
Register      Login
Sexual Health Sexual Health Society
Publishing on sexual health from the widest perspective
Shopping Cart: ( empty )
You are here: Home > Journals > SH > SH09129
EDITORIAL
Contents Vol 7(3)

For debate: that Australia should continue using the quadrivalent vaccine

Gerard Wain
+ Author Affiliations
- Author Affiliations

Department of Gynaecological Oncology, Westmead Hospital, NSW 2145, Australia. Email: gerard.wain@wsahs.nsw.gov.au

Sexual Health 7(3) 235-237 https://doi.org/10.1071/SH09129
Submitted: 29 November 2009  Accepted: 28 January 2010   Published: 19 August 2010


References


[1] Pharmaceutical Benefits Advisory Committee (PBAC). Final public summary document. November 2006 PBAC Meeting. Canberra: PBAC. Available online at: http://www.health.gov.au/internet/main/publishing.nsf/Content/pbac-psd-gardasil-nov06 [verified November 2009].

[2] Kulasingam S,  Connelly L,  Conway E,  Hocking J,  Myers E,  Regan D, et al. A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Screening Program. Sexual Health 2007; 4 165–75.
| Crossref | GoogleScholarGoogle Scholar | PubMed | [verified November 2009].

[9] Stanley M. A practitioner’s guide to understanding immunity to human papillomavirus. US Obst Gynecol 2009; 4 2–7.
[verified November 2009].

[11] Markowitz L. Review of bivalent HPV vaccine & comparative of HPV2 & HPV4. Atlanta: Centers for Disease Control and Prevention. Available online at: http://www.cdc.gov/vaccines/recs/acip/slides-oct09.htm#hpv [verified November 2009].

[12] NCIRS. Fact sheet: human papillomavirus vaccines for Australians: information for GPs and other immunisation providers. Sydney: National Centre for Immunisation Research and Surveillance. Available online at: http://www.ncirs.usyd.edu.au/facts/hpv_april_2009_bw.pdf [verified November 2009].

[13] Einstein MH,  Baron M,  Levin MJ,  Chatterjee A,  Edwards RP,  Zepp F, et al. Comparison of the immunogenicity and safety of Cervarix® and Gardasil® human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years. Hum Vaccin 2009; 5 705–19.
| Crossref | GoogleScholarGoogle Scholar | CAS | PubMed | [verified December 2009].

[15] Jit M,  Choi YH,  Edmunds WJ. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 2008; 337 a769.
| Crossref | GoogleScholarGoogle Scholar | PubMed | [verified November 2009].

[19] Leinonen M,  Nieminen P,  Kotaniemi-Talonen L,  Malila N,  Tarkkanen J,  Laurila P, et al. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting. J Natl Cancer Inst 2009; 101 1–12.
| Crossref | GoogleScholarGoogle Scholar |